Medicinal composition comprising a non-coding RNA molecule and an antibody targeting a tumor antigen

Patent metadata

Field	Value
Publication number	US-11944636-B2
Application number	US-202017094903-A
Country	US
Kind code	B2
Filing date	Nov 11, 2020
Priority date	Sep 17, 2020
Publication date	Apr 2, 2024
Grant date	Apr 2, 2024

Abstract

This invention discloses a medicinal composition includes a non-coding RNA molecule and an antibody targeting a tumor antigen for preventing and/or treating cancer. This invention uses the synergistic combination of a non-coding RNA molecule or its functional variant or homologue, and an antibody targeting a tumor antigen to prevent and/or treat cancer, thereby providing a novel and effective method in preventing and/or treating various cancers.

First claim

The invention claimed is:

1. A medicinal composition for preventing and/or treating cancer comprising a non-coding RNA molecule and an antibody targeting a tumor antigen,
wherein the non-coding RNA molecule is a tRNA molecule comprising an antisense strand having a sequence identity of at least 90% with respect to SEQ ID NO: 1, and a sense strand having a sequence identity of at least 90% with respect to SEQ ID NO: 2, and
wherein the antibody targets a PD-1 tumor antigen; and
wherein said non-coding RNA molecule and said antibody targeting a tumor antigen may be administered to a patient as a mixture of said non-coding RNA molecule and said antibody targeting a tumor antigen; or said non-coding RNA molecule and said antibody targeting a tumor antigen may be administered to a patient separately.

2. The medicinal composition of claim 1 , wherein a mass ratio of the non-coding RNA molecule, and the antibody targeting a tumor antigen is between 1:250 and 1:100.

3. The medicinal composition of claim 1 , further comprises a pharmaceutically acceptable carrier, a diluent or an excipient.

4. The medicinal composition of claim 3 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of a viral vector, a collagen, a polymer, a polypeptide, a protamine, a lipid-forming liposome, and any combination thereof.

5. The medicinal composition of claim 4 , wherein the pharmaceutically acceptable carrier comprises a polypeptide or a histidine-lysine polymer.

6. The medicinal composition of claim 1 , further comprises other medicine for preventing and/or treating cancer, and/or a nucleic acid stabilizer.

7. The medicinal composition of claim 1 , wherein the medicinal composition has a dosage form for subcutaneous, intravenous, intraperitoneal or intramuscular injection.

8. A kit comprising a medicinal composition according to claim 1 .

9. The kit of claim 8 , wherein the non-coding RNA molecule and the antibody targeting a tumor antigen are provided in separate containers, and each of them is provided in a dosage form for subcutaneous, intravenous, intraperitoneal or intramuscular injection.

10. The medicinal composition of claim 2 , wherein the mass ratio of the non-coding RNA molecule, and the antibody targeting a tumor antigen is 1:125.

11. The medicinal composition of claim 1 , wherein the non-coding RNA molecule is a double-stranded tRNA molecule.

12. The medicinal composition according to claim 3 , wherein the pharmaceutically acceptable carrier comprises a gene delivery vector or a material encapsulating the non-coding RNA molecule to form nanoparticles.

13. The medicinal composition of claim 1 wherein the non-coding RNA molecule is a tRNA molecule consisting of an antisense strand having a sequence identity of at least 90% with respect to SEQ ID NO: 1, and a sense strand having a sequence identity of at least 90% with respect to SEQ ID NO: 2.

14. The medicinal composition of claim 1 wherein said antisense strand is SEQ ID NO: 1.

15. The medicinal composition of claim 1 wherein said sense strand is SEQ ID NO: 2.

Assignees

• Univ Macau Sci & Tech

Inventors

• Jiang zhi-hong
• Yau Lee-Fong
• Tong tian-tian
• Huang Hao
• Hu Kua
• Leung Elaine Lai-Han

Classifications

• A61K31/7105 Primary

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

• A61K31/713

  Double-stranded nucleic acids or oligonucleotides · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• C07K16/2818 Primary

  against CD28 or CD152 · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title